Skip to main content

Table 2 Demographics and baseline characteristics

From: Cardiovascular safety assessment of pramlintide in type 2 diabetes: results from a pooled analysis of five clinical trials

Variable

Pramlintide (n = 1434)

Pooled comparator (n = 582)

Sex

 Male

738 (51.5)

315 (54.1)

 Female

696 (48.5)

267 (45.9)

Age (years)

57.2 ± 10.1

55.7 ± 10.2

Race

 White

1184 (82.6)

467 (80.2)

 Black

136 (9.5)

57 (9.8)

 Asian

7 (0.5)

3 (0.5)

 Hispanic

93 (6.5)

47 (8.1)

 Other

14 (1.0)

8 (1.4)

Body weight (kg)

93.6 ± 19.9

94.4 ± 19.6

Body mass index (kg/m2)

32.4 ± 6.2

32.6 ± 6.4

HbA1c (%)

9.1 ± 1.2

9.0 ± 1.3

Duration of diabetes (years)

12.6 ± 7.3

12.0 ± 7.0

  1. Data are shown as n (%) or mean ± standard deviation
  2. HbA1c glycated hemoglobin